- Home
- BLCO vs QURE Comparison
BLCO vs QURE Comparison
Compare BLCO & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLCO
- QURE
- Stock Information
- Founded
- BLCO 1853
- QURE 1998
- Country
- BLCO Canada
- QURE Netherlands
- Employees
- BLCO N/A
- QURE N/A
- Industry
- BLCO Ophthalmic Goods
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- BLCO Health Care
- QURE Health Care
- Exchange
- BLCO Nasdaq
- QURE Nasdaq
- Market Cap
- BLCO 5.2B
- QURE 4.3B
- IPO Year
- BLCO 2022
- QURE 2007
- Fundamental
- Price
- BLCO $15.61
- QURE $27.72
- Analyst Decision
- BLCO Hold
- QURE Strong Buy
- Analyst Count
- BLCO 14
- QURE 13
- Target Price
- BLCO $16.46
- QURE $64.67
- AVG Volume (30 Days)
- BLCO 531.9K
- QURE 4.2M
- Earning Date
- BLCO 10-29-2025
- QURE 11-10-2025
- Dividend Yield
- BLCO N/A
- QURE N/A
- EPS Growth
- BLCO N/A
- QURE N/A
- EPS
- BLCO N/A
- QURE N/A
- Revenue
- BLCO $4,976,000,000.00
- QURE $14,337,000.00
- Revenue This Year
- BLCO $8.12
- QURE N/A
- Revenue Next Year
- BLCO $5.81
- QURE $229.18
- P/E Ratio
- BLCO N/A
- QURE N/A
- Revenue Growth
- BLCO 6.23
- QURE N/A
- 52 Week Low
- BLCO $10.45
- QURE $5.50
- 52 Week High
- BLCO $20.71
- QURE $71.50
- Technical
- Relative Strength Index (RSI)
- BLCO 56.34
- QURE 31.43
- Support Level
- BLCO $14.89
- QURE $25.52
- Resistance Level
- BLCO $16.00
- QURE $71.50
- Average True Range (ATR)
- BLCO 0.52
- QURE 4.38
- MACD
- BLCO -0.00
- QURE -5.84
- Stochastic Oscillator
- BLCO 72.14
- QURE 10.91
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.